AB Science Valuation Multiples

AB Science Overview

About AB Science

AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.

Founded

2001

HQ

Employees

103

Website

ab-science.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1M

EBITDA: ($7M)

EV

$115M

Valuation Multiples

Multiples.vc

Start free trial

AB Science Financials

AB Science reported last 12-month revenue of $1M and negative EBITDA of ($7M).

In the same LTM period, AB Science generated $473K in gross profit, ($7M) in EBITDA losses, and had net loss of ($10M).

AB Science P&L

In the most recent fiscal year, AB Science reported revenue of $1M and EBITDA of ($6M).

AB Science expects next 12-month revenue of XXX and NTM EBITDA of XXX

AB Science Stock Performance

AB Science has current market cap of $99M, and enterprise value of $115M.

AB Science's stock price is $1.50.

AB Science Valuation Multiples

AB Science trades at 90.3x EV/Revenue multiple, and (16.0x) EV/EBITDA.

AB Science Financial Valuation Multiples

As of March 19, 2026, AB Science has market cap of $99M and EV of $115M.

Equity research analysts estimate AB Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AB Science has a P/E ratio of (9.6x).

AB Science Margins & Growth Rates

AB Science's revenue in the last 12 month grew by 6%.

AB Science's revenue per employee in the last FY averaged $0.0M.

AB Science's rule of 40 is (558%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AB Science's rule of X is (549%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

AB Science Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

AB Science M&A Activity

AB Science acquired XXX companies to date.

Last acquisition by AB Science was on XXXXXXXX, XXXXX. AB Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AB Science Investment Activity

AB Science invested in XXX companies to date.

AB Science made its latest investment on XXXXXXXX, XXXXX. AB Science invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).